收藏切换
Advances in targeting KRAS mutations for immunotherapy of pancreatic cancer
收藏切换
Xi-yan ZHANG, Zong-gen PENG, Shu-zhen CHEN*
Acta Pharmaceutica Sinica | 2026, 61(9) : 3292 - 3301
Less
收藏切换
Acta Pharmaceutica Sinica | 2026, 61(9): 3292-3301
• Reviews •
Advances in targeting KRAS mutations for immunotherapy of pancreatic cancer
Full
Xi-yan ZHANG, Zong-gen PENG, Shu-zhen CHEN*
Affiliations
  • State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100050, China
Published: 2026-09-12 doi: 10.16438/j.0513-4870.2026-0366
Outline
收藏切换

Pancreatic cancer is one of the digestive system malignancies with the poorest prognosis, with a five-year survival rate of only approximately 13%, and even lower at 8.5% in the Chinese population. Due to difficulties in early diagnosis, most patients are already at an advanced stage at the time of diagnosis, with limited treatment options and a propensity for resistance to radiotherapy and chemotherapy. KRAS (kirsten rat sarcoma viral oncogene homolog) mutations occur in over 90% of pancreatic cancer cases. Mutant KRAS not only drives tumor proliferation but also remodels the immune microenvironment through various mechanisms, such as inducing infiltration of immunosuppressive cells and upregulating immune checkpoint molecules, thereby leading to immune evasion. In recent years, with the introduction of KRAS inhibitors into clinical practice, targeting KRAS has shown potential for remodeling the tumor immune microenvironment. This article systematically reviews the mechanisms by which KRAS mutations contribute to the formation of an immunosuppressive microenvironment in pancreatic cancer, the progress in the development of KRAS-targeted drugs, and the current status and challenges of their combination with immunotherapy, providing new insights for precision treatment of pancreatic cancer.

pancreatic cancer  /  KRAS mutation  /  immunosuppression  /  immunotherapy  /  targeted therapy
张析妍, 彭宗根, 陈淑珍. 靶向KRAS突变在胰腺癌免疫治疗中的研究进展. 药学学报, 2026 , 61 (9) : 3292 -3301 . DOI: 10.16438/j.0513-4870.2026-0366
Xi-yan ZHANG, Zong-gen PENG, Shu-zhen CHEN. Advances in targeting KRAS mutations for immunotherapy of pancreatic cancer[J]. Acta Pharmaceutica Sinica, 2026 , 61 (9) : 3292 -3301 . DOI: 10.16438/j.0513-4870.2026-0366
Year 2026 volume 61 Issue 9
132
58
Cite this Article
BibTeX
Article Info
doi: 10.16438/j.0513-4870.2026-0366
  • Receive Date:2026-04-01
  • Online Date:2026-10-22
  • Published:2026-09-12
Article Data
Affiliations
History
  • Received:2026-04-01
  • Revised:2026-05-06
Affiliations
    State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100050, China
References
Share
https://castjournals.cast.org.cn/joweb/yxxb/EN/10.16438/j.0513-4870.2026-0366
Share to
QR

Scan QR to access full text

Cite this article
BibTeX
Citations
表12种不同金属材料的力学参数
科
Family
属数
Number of
genus
种数
Number of
species
占总种数比例
Percentage of
total species (%)
属
Genus
种数
Number of
species
占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏
  • BibTeX
  • EndNote
  • RefWorks
  • TxT